---
figid: PMC4928369__itt-2-073Fig3
figlink: /pmc/articles/PMC4928369/figure/f3-itt-2-073/
number: F3
caption: 'Site of actions of targeted therapy used in the treatment of metastatic
  renal cell carcinoma.Notes: The tumor cell possesses inactive Von Hippel–Lindau
  (VHL), permitting the production of heterodimerized hypoxia-inducible factor (HIF)
  under normoxic conditions. Mammalian target of rapamycin (mTOR) activation further
  facilitates HIF production. HIF and S6 contribute to gene activation, leading to
  production of vascular endothelial growth factor (VEGF) and platelet-derived growth
  factor (PDGF), both of which act upon the endothelial cell to promote angiogenesis.
  Bevacizumab targets only VEGF, whereas sunitinib and sorafenib target VEGF receptors
  as well as PDGF and c-kit. Temsirolimus and everolimus inhibit the mTOR signaling
  pathway. Dendritic cells (DCs) are crucial in antitumor immunity, and mature DCs
  interact with both innate immune cells and antigen-specific T cells to elicit an
  immune response against tumor antigens. Tumor-derived factors such as VEGF, interleukin
  (IL)-6, and IL-8 may inhibit DC maturation, therefore escaping immune surveillance.
  Nontargeted therapies such as interferon (IFN)-α (by promoting maturation of DCs)
  and DC-based vaccination (by presenting tumor antigens to induce an antigen-specific
  cytotoxic T-cell response) are other effective treatment options for metastatic
  renal cell carcinoma.Abbreviations: MHC, major histocompatibility complex; PI3-K,
  phosphatidylinositide 3-kinase; MIP, macrophage inflammatory protein; X, site of
  action; VEGF, vascular endothelial growth factor; FKBP, FK-binding protein; IGF,
  insulin-like growth factor, PDGFR, platelet-derived growth factor receptor.'
pmcid: PMC4928369
papertitle: 'Metastatic renal cell carcinoma: update on epidemiology, genetics, and
  therapeutic modalities.'
reftext: Angela Graves, et al. Immunotargets Ther. 2013;2:73-90.
pmc_ranked_result_index: '125363'
pathway_score: 0.9580294
filename: itt-2-073Fig3.jpg
figtitle: 'Metastatic renal cell carcinoma: update on epidemiology, genetics, and
  therapeutic modalities.'
year: '2013'
organisms:
- Homo sapiens
ndex: bedeb491-dee3-11ea-99da-0ac135e8bacf
annotations: []
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC4928369__itt-2-073Fig3.html
  '@type': Dataset
  description: 'Site of actions of targeted therapy used in the treatment of metastatic
    renal cell carcinoma.Notes: The tumor cell possesses inactive Von Hippel–Lindau
    (VHL), permitting the production of heterodimerized hypoxia-inducible factor (HIF)
    under normoxic conditions. Mammalian target of rapamycin (mTOR) activation further
    facilitates HIF production. HIF and S6 contribute to gene activation, leading
    to production of vascular endothelial growth factor (VEGF) and platelet-derived
    growth factor (PDGF), both of which act upon the endothelial cell to promote angiogenesis.
    Bevacizumab targets only VEGF, whereas sunitinib and sorafenib target VEGF receptors
    as well as PDGF and c-kit. Temsirolimus and everolimus inhibit the mTOR signaling
    pathway. Dendritic cells (DCs) are crucial in antitumor immunity, and mature DCs
    interact with both innate immune cells and antigen-specific T cells to elicit
    an immune response against tumor antigens. Tumor-derived factors such as VEGF,
    interleukin (IL)-6, and IL-8 may inhibit DC maturation, therefore escaping immune
    surveillance. Nontargeted therapies such as interferon (IFN)-α (by promoting maturation
    of DCs) and DC-based vaccination (by presenting tumor antigens to induce an antigen-specific
    cytotoxic T-cell response) are other effective treatment options for metastatic
    renal cell carcinoma.Abbreviations: MHC, major histocompatibility complex; PI3-K,
    phosphatidylinositide 3-kinase; MIP, macrophage inflammatory protein; X, site
    of action; VEGF, vascular endothelial growth factor; FKBP, FK-binding protein;
    IGF, insulin-like growth factor, PDGFR, platelet-derived growth factor receptor.'
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - PDGFA
  - MTOR
  - PIK3CD
  - AKT3
  - MLST8
  - MAPKAP1
  - PDGFC
  - PIK3CG
  - RICTOR
  - FLT4
  - KDR
  - PDGFB
  - PIK3CB
  - AKT1
  - AKT2
  - VHL
  - PIK3R6
  - CD8B
  - EPAS1
  - CD4
  - CD8A
  - FLT1
  - CCL20
  - CXCL8
  - PIK3R5
  - VEGFA
  - PIK3R4
  - PIK3CA
  - PGF
  - IL6
  - PIK3R3
  - VEGFD
  - PDGFRB
  - HIF3A
  - PDGFD
  - PDGFRA
  - VEGFC
  - HIF1A
  - VEGFB
  - Cancer
genes:
- word: PDGF
  symbol: PDGF
  source: bioentities_symbol
  hgnc_symbol: PDGFA
  entrez: '5154'
- word: MTORC2
  symbol: mTORC2
  source: bioentities_symbol
  hgnc_symbol: MTOR
  entrez: '2475'
- word: PI3-K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CD
  entrez: '5293'
- word: AKt
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT3
  entrez: '10000'
- word: MTORC2
  symbol: mTORC2
  source: bioentities_symbol
  hgnc_symbol: MLST8
  entrez: '64223'
- word: MTORC2
  symbol: mTORC2
  source: bioentities_symbol
  hgnc_symbol: MAPKAP1
  entrez: '79109'
- word: PDGF
  symbol: PDGF
  source: bioentities_symbol
  hgnc_symbol: PDGFC
  entrez: '56034'
- word: PI3-K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CG
  entrez: '5294'
- word: MTORC2
  symbol: mTORC2
  source: bioentities_symbol
  hgnc_symbol: RICTOR
  entrez: '253260'
- word: MTOR
  symbol: MTOR
  source: hgnc_symbol
  hgnc_symbol: MTOR
  entrez: '2475'
- word: VEGFR
  symbol: VEGFR
  source: bioentities_symbol
  hgnc_symbol: FLT4
  entrez: '2324'
- word: VEGFR
  symbol: VEGFR
  source: bioentities_symbol
  hgnc_symbol: KDR
  entrez: '3791'
- word: PDGF
  symbol: PDGF
  source: bioentities_symbol
  hgnc_symbol: PDGFB
  entrez: '5155'
- word: PI3-K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CB
  entrez: '5291'
- word: AKt
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT1
  entrez: '207'
- word: AKt
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT2
  entrez: '208'
- word: VHL
  symbol: VHL
  source: hgnc_symbol
  hgnc_symbol: VHL
  entrez: '7428'
- word: PI3-K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R6
  entrez: '146850'
- word: CD8'
  symbol: CD8
  source: bioentities_symbol
  hgnc_symbol: CD8B
  entrez: '926'
- word: HIFa
  symbol: HIF_alpha
  source: bioentities_symbol
  hgnc_symbol: EPAS1
  entrez: '2034'
- word: CD4
  symbol: CD4
  source: hgnc_symbol
  hgnc_symbol: CD4
  entrez: '920'
- word: CD8'
  symbol: CD8
  source: bioentities_symbol
  hgnc_symbol: CD8A
  entrez: '925'
- word: VEGFR
  symbol: VEGFR
  source: bioentities_symbol
  hgnc_symbol: FLT1
  entrez: '2321'
- word: MIP-3a
  symbol: MIP-3a
  source: hgnc_alias_symbol
  hgnc_symbol: CCL20
  entrez: '6364'
- word: IL-8
  symbol: IL-8
  source: hgnc_alias_symbol
  hgnc_symbol: CXCL8
  entrez: '3576'
- word: PI3-K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R5
  entrez: '23533'
- word: VEGF
  symbol: VEGF
  source: bioentities_symbol
  hgnc_symbol: VEGFA
  entrez: '7422'
- word: PI3-K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R4
  entrez: '30849'
- word: PI3-K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CA
  entrez: '5290'
- word: VEGF
  symbol: VEGF
  source: bioentities_symbol
  hgnc_symbol: PGF
  entrez: '5228'
- word: IL-6
  symbol: IL-6
  source: hgnc_alias_symbol
  hgnc_symbol: IL6
  entrez: '3569'
- word: PI3-K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R3
  entrez: '8503'
- word: VEGF
  symbol: VEGF
  source: bioentities_symbol
  hgnc_symbol: VEGFD
  entrez: '2277'
- word: PDGFR
  symbol: PDGFR
  source: bioentities_symbol
  hgnc_symbol: PDGFRB
  entrez: '5159'
- word: HIFa
  symbol: HIF_alpha
  source: bioentities_symbol
  hgnc_symbol: HIF3A
  entrez: '64344'
- word: PDGF
  symbol: PDGF
  source: bioentities_symbol
  hgnc_symbol: PDGFD
  entrez: '80310'
- word: PDGFR
  symbol: PDGFR
  source: bioentities_symbol
  hgnc_symbol: PDGFRA
  entrez: '5156'
- word: VEGF
  symbol: VEGF
  source: bioentities_symbol
  hgnc_symbol: VEGFC
  entrez: '7424'
- word: HIFa
  symbol: HIF_alpha
  source: bioentities_symbol
  hgnc_symbol: HIF1A
  entrez: '3091'
- word: VEGF
  symbol: VEGF
  source: bioentities_symbol
  hgnc_symbol: VEGFB
  entrez: '7423'
chemicals: []
diseases:
- word: Cancer
  source: ''
  identifier: ''
figid_alias: PMC4928369__F3
redirect_from: /figures/PMC4928369__F3
figtype: Figure
---
